Hani Babiker, MD, describes the setting of FDA approval on tumor treatment fields

00:19 •

Hani Babiker, MD, describes the setting of FDA approval on tumor treatment fields

Related Videos

Charles Rudin, MD, PhD, shares the take home message regarding Keynote-604 for lung cancer treatment

Charles Rudin, MD, PhD, shares the take home message regarding Keynote-604 for lung cancer treatment

$Alti Rahman, MHA\MBA, CSSBB, offers advice to oncology practices in today's cancer care landscape$

Alti Rahman, MHA\MBA, CSSBB, offers advice to oncology practices in today's cancer care landscape

Johnetta Blakely, MD, reflects on the progress and innovation of community oncologists

Johnetta Blakely, MD, reflects on the progress and innovation of community oncologists

Sibel Blau, MD, tells us more about IQ Oncology

Sibel Blau, MD, tells us more about IQ Oncology

Alexander Spira, MD, PhD, FACP, on managing lung cancer patients in a community setting

Alexander Spira, MD, PhD, FACP, on managing lung cancer patients in a community setting

Kim N. Chi, MD, on what findings from the Phase III TITAN study mean for patients

Kim N. Chi, MD, on what findings from the Phase III TITAN study mean for patients

Jeff Patton, MD, discusses his new role with the Community Oncology Alliance (COA)

Jeff Patton, MD, discusses his new role with the Community Oncology Alliance (COA)

The impact of clinical pathways on quality cancer care as explained by Bruce Gould, MD

The impact of clinical pathways on quality cancer care as explained by Bruce Gould, MD

Michael Diaz, MD, on how community oncology is shaping the future of cancer care

Michael Diaz, MD, on how community oncology is shaping the future of cancer care

Una Hopkins, RN, regarding cancer survivorship resulting from expanded use of immune-oncology agents

Una Hopkins, RN, regarding cancer survivorship resulting from expanded use of immune-oncology agents

Debra Patt, MD, on why it is important for community oncologists to partner with associations

Debra Patt, MD, on why it is important for community oncologists to partner with associations

Dan Wygal provides perspective on value-based contracting in oncology

Dan Wygal provides perspective on value-based contracting in oncology

Sibel Blau, MD, speculates on the role of telehealth in cancer management

Sibel Blau, MD, speculates on the role of telehealth in cancer management

Brad Prechtl tells how his practice is working to improve cancer care

Brad Prechtl tells how his practice is working to improve cancer care

Jennie Crews, MD, MMM, FACP, explains how to maintain the delivery of quality cancer care

Jennie Crews, MD, MMM, FACP, explains how to maintain the delivery of quality cancer care

Dana Chase, MD, shares details about PRIMA and PAOLA clinical studies regarding ovarian cancer

Dana Chase, MD, shares details about PRIMA and PAOLA clinical studies regarding ovarian cancer

Banu Arun, MD, regarding the optimal setting for PARP inhibitors in breast cancer treatment

Banu Arun, MD, regarding the optimal setting for PARP inhibitors in breast cancer treatment

Jeff Vacirca, MD, shares his thoughts on the “Medicare Experiment” on community oncology

Jeff Vacirca, MD, shares his thoughts on the “Medicare Experiment” on community oncology

Ghassan Abou-Alfa, MD, explains how new agents in advanced HCC are being integrated into treatment

Ghassan Abou-Alfa, MD, explains how new agents in advanced HCC are being integrated into treatment